Global Liquid Biopsy Market by Products & Services (Reagents & Kits, Equipment, and Services), By Sample (Cell Free DNA, Circulating Tumor Cells, and Exosomes), By Application (Oncology Testing, Non-Invasive Prenatal Testing, and Transplant Care), By End User (Hospitals, Research Laboratories, Diagnostic Laboratories, and Patients) and by Geography - Trends and Forecast to 2025

  • Published On : Jan 2018 |
  • Pages : 181 Pages |
  • Format :  

Liquid Biopsy Market - Insights

Liquid biopsy involves testing of the blood to identify biomarkers or cancer cells in the form of cells or pieces of DNA which are separated from the tumor and are circulating in the blood. Liquid biopsy helps in early detection of cancer, which would aid in adopting an optimal treatment plan. It is a non-invasive technique, which makes frequent testing possible, and effectiveness of cancer treatment can also be validated using it. The procedure requires only a small amount of blood sample of around 5 milliliters and the procedure is quicker, which is easily tolerated by the patients, making it a viable alternative for conventional biopsy techniques such as tissue biopsy. Liquid biopsy makes use of blood tests to identify presence of certain tumor cells such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes. Some of the commercially available liquid biopsy tests for cancer are Cologurad, Guardant360, Oncotype SEQ Liquid Select, and Target Selector liquid biopsy assays. However, in December 2017, two Johns Hopkins prostate cancer researchers found differences in the results from two different liquid biopsy providers and such inconsistencies in results may hinder the growth of the market.

Rising applications of liquid biopsy owing to its advantages over conventional biopsy is expected to boost growth of the liquid biopsy market

Liquid biopsy allows for efficient disease management as well as non-invasive prenatal testing (NIPT). Non–invasive prenatal testing enables diagnosis of potential risks of developing chromosomal abnormalities such as Edwards’s syndrome, Down syndrome, and X and Y chromosome abnormalities. It offers advantages such as frequent use with less risks as the sample is taken from blood only, offering complete genetic profile of the patient by providing DNA for more than one tumor; highly non-invasive technique; no biases in results, due to heterogeneity of the tumor tissues; requirement of small amount of sample; and cost and time effectiveness wherein, liquid biopsy addresses all these issues associated with conventional tissue biopsy. Furthermore, applications of liquid biopsy for diagnosis of non-small cell lung cancer (NSCLC), breast cancer, coronary heart disease, prostate cancer, etc. is increasing. For instance, according to a new study published in Oncology Journal, January 2018, the liquid biopsy combo involving exosomal RNA and cell-free DNA (cfDNA) improved the sensitivity of epidermal growth factor mutations in NSCLC. Furthermore, OncoCyte Corporation presented positive data from its breast cancer diagnostic test study, in December 2017, at San Antonio Breast Cancer Symposium.

The global liquid biopsy market was valued at US$ 1,824.7 million in 2016 and is expected to witness a robust CAGR of 18.3% over the forecast period (2017–2025).

Figure 1. Global Liquid Biopsy Market Share, by Application (%) 2017 and 2025

Liquid Biopsy Market

   Source: Coherent Market Insights Analysis (2017)

Manufacturers are focusing on development of new tests in the liquid biopsy market and this is expected to bolster growth of the liquid biopsy market over the forecast period

Established as well as small players in the liquid biopsy market are actively focusing on research and development of methods in liquid biopsy through collaborations. For instance, Biodesix—a U.S.-based company—developed a novel way of extract circulating RNA from plasma in November 2017, in collaboration with Norgen Biotek. Moreover, Precipio—a U.S.-based organization, entered into merger agreement with Transgenomic, in 2017, for commercializing ICE COLD PCR (ICP) for liquid biopsies, which preferentially enriches mutant DNA sequences over wild-type DNA through selective amplification. HaploX Biotechnology—a China-based company—raised US$ 32 Mn in financing, in January 2018, in order to integrate liquid biopsy technology, artificial intelligence, and gene sequencing.

Furthermore, in May 2017, Guardant Health, Inc. raised US$ 360 million to create cancer blood tests to deploy its test for 1 million people over the next five years. Guardant Health and MD Anderson Cancer Center launched liquid biopsy partnership, in February 2017, under which Guardant is expected to help MD Anderson to build multiple on-site liquid biopsy centers. Guardant Health announced broad, long term alliance with Pfizer Oncology to support multiple clinical programs with its Guardant360 assay, in June 2017. Moreover, Guardant Health announced that it entered into separate agreements with AstraZeneca, Merck, Merck KGaA, and Darmstadt in January 2017 to develop 500 plus gene liquid biopsy panel to speed up clinical trials and drug development. Natera collaborated with Baylor Genetics to develop a non-invasive prenatal test, Vistara, in May 2017, which aided in detecting de novo mutations in single gene disorders.

Some major players operating in the liquid biopsy market include Illumina, Inc., Roche AG, Natera, Inc., Laboratory Corporation of America Holdings (LabCorp), Qiagen N.V., Thermo Fisher Scientific Inc., Exact Sciences Corp., Biocept, Inc., Genomic Health, Inc., Guardant Health, TrovaGene Inc., CareDx Inc., Adaptive Biotechnologies Corporation, and Biocartis SA.

Liquid biopsy gained popularity among physicians owing to increasing importance of precision medicine and advantages offered by the liquid biopsy over conventional biopsy techniques. Clinical diagnosis of tumors is done by pathological testing and medical imaging in which pathological testing involves tissue biopsies, molecular pathology tests, and serological indicators tests. Among these techniques tissue biopsy is considered as a gold standard for diagnosis. However, it has certain disadvantages such as difficulty in obtaining tissues from terminal cancer patients, complications due to sampling, and result difference due to tumor heterogeneity. Liquid biopsy provides more accurate results and offers more advantages over conventional techniques. It uses circulating tumor cell detection and cell free DNA etc. techniques for early detection of the cancer.

Market Dynamics

Factors such as rising prevalence of various cancers, rising demand for minimally invasive procedures, and advantages offered by liquid biopsy over conventional tissue biopsy are supporting growth of the liquid biopsy market. Liquid biopsy offers advantages over conventional tissue biopsy such as early disease detection, real-time monitoring of the metastasis and actual treatment response, detection of primary tumors and metastasis through simple and non-invasive tests, and may be cheaper than conventional biopsy. Furthermore, prevalence of various cancers is increasing and according to National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer are diagnosed in the U.S., with an around 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024, indicating need for early disease diagnosis and treatment. Demand for minimally invasive treatments is also increasing as tissue biopsy is an invasive approach for cancer diagnosis, wherein, liquid biopsy is more convenient, which is expected to boost growth of the liquid biopsy market.

Key features of the study:

  • This report provides in-depth analysis of liquid biopsy market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global liquid biopsy market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key companies covered as a part of this study include Illumina, Inc., Roche AG, Natera, Inc., Laboratory Corporation of America Holdings (LabCorp), Qiagen N.V., Thermo Fisher Scientific Inc., Exact Sciences Corp., Biocept, Inc., Genomic Health, Inc., Guardant Health, TrovaGene Inc., CareDx Inc., Adaptive Biotechnologies Corporation, and Biocartis SA.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global liquid biopsy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the liquid biopsy market

Detailed Segmentation:

  • Global Liquid Biopsy Market, By Products & Services:
    • Reagents & Kits     
    • Equipments
    • Services
  • Global Liquid Biopsy Market, By Sample:
    • Cell Free DNA (cfDNA)      
    • Circulating Tumor Cells (CTC)
    • Exosomes
  • Global Liquid Biopsy Market, By Application:
    • Oncology Testing
    • Noninvasive Prenatal Testing
    • Transplant Care     
  • Global Liquid Biopsy Market, By End User:
    • Hospitals     
    • Research Laboratories
    • Diagnostic Laboratories
    • Patients
  • Global Liquid Biopsy Market, By Geography:
    • North America
      • By Product & Services:
        • Reagents & Kits     
        • Equipments
        • Services
      • By Sample:
        • Cell Free DNA (cfDNA)      
        • Circulating Tumor Cells (CTC)
        • Exosomes
      • By Application:
        • Oncology Testing
        • Noninvasive Prenatal Testing
        • Transplant Care     
      • By End User:
        • Hospitals     
        • Research Laboratories
        • Diagnostic Laboratories
        • Patients
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Product & Services:
        • Reagents & Kits     
        • Equipments
        • Services
      • By Sample:
        • Cell Free DNA (cfDNA)      
        • Circulating Tumor Cells (CTC)
        • Exosomes
      • By Application:
        • Oncology Testing
        • Noninvasive Prenatal Testing
        • Transplant Care     
      • By End User:
        • Hospitals     
        • Research Laboratories
        • Diagnostic Laboratories
        • Patients
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product & Services:
        • Reagents & Kits     
        • Equipments
        • Services
      • By Sample:
        • Cell Free DNA (cfDNA)      
        • Circulating Tumor Cells (CTC)
        • Exosomes
      • By Application:
        • Oncology Testing
        • Noninvasive Prenatal Testing
        • Transplant Care     
      • By End User:
        • Hospitals     
        • Research Laboratories
        • Diagnostic Laboratories
        • Patients
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Product & Services:
        • Reagents & Kits     
        • Equipments
        • Services
      • By Sample:
        • Cell Free DNA (cfDNA)      
        • Circulating Tumor Cells (CTC)
        • Exosomes
      • By Application:
        • Oncology Testing
        • Noninvasive Prenatal Testing
        • Transplant Care     
      • By End User:
        • Hospitals     
        • Research Laboratories
        • Diagnostic Laboratories
        • Patients
      • By Country:
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East
      • By Product & Services:
        • Reagents & Kits     
        • Equipments
        • Services
      • By Sample:
        • Cell Free DNA (cfDNA)      
        • Circulating Tumor Cells (CTC)
        • Exosomes
      • By Application:
        • Oncology Testing
        • Noninvasive Prenatal Testing
        • Transplant Care     
      • By End User:
        • Hospitals     
        • Research Laboratories
        • Diagnostic Laboratories
        • Patients
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product & Services:
        • Reagents & Kits     
        • Equipments
        • Services
      • By Sample:
        • Cell Free DNA (cfDNA)      
        • Circulating Tumor Cells (CTC)
        • Exosomes
      • By Application:
        • Oncology Testing
        • Noninvasive Prenatal Testing
        • Transplant Care     
      • By End User:
        • Hospitals     
        • Research Laboratories
        • Diagnostic Laboratories
        • Patients
      • By Country:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
  • Roche AG *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
  • Illumina, Inc.
  • Natera Inc.
  • Laboratory Corporation of America Holdings
  • Qiagen N.V.
  • Thermo Fisher Scientific
  • Exact Sciences Corp.
  • Biocept, Inc.
  • Genomic Health, Inc.
  • Guardant Health
  • CareDx Inc.
  • Adaptive Biotechnologies Corporation
  • Biocartis SA.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Products & Services
      • Market Snippet, By Sample
      • Market Snippet, By Application
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Regulatory Scenario
    • Technological Evolution
    • Mergers & Acquisition
    • Pipeline Analysis
    • Recently Launched Products
  4. Global Liquid Biopsy Market, By Products & Services, 2017–2025 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017–2025
      • Segment Trends
    • Reagents & Kits
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Mn)
    • Equipments
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Mn)
    • Services
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Mn)
  5. Global Liquid Biopsy Market, By Sample, 2017–2025 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017–2025
      • Segment Trends
    • Cell Free DNA (cfDNA)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Mn)
    • Circulating Tumor Cells (CTC)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Mn)
    • Exosomes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Mn)
  6. Global Liquid Biopsy Market, By Application, 2017–2025 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017–2025
      • Segment Trends
    • Oncology Testing
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Mn)
    • Noninvasive Prenatal Testing (NIPT)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Mn)
    • Transplant Care
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Mn)
  7. Global Liquid Biopsy Market, By End User, 2017–2025 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017–2025
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Mn)
    • Research Laboratories
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Mn)
    • Diagnostic Laboratories
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Mn)
    • Patients
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2025, (US$ Mn)
  8. Global Liquid Biopsy Market, By Regions, 2017–2025 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2025
    • North America
      • Market Size and Forecast, By Products & Services, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Sample, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Application, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By End User, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2017–2025 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Products & Services, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Sample, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Application, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By End User, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2017–2025 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Products & Services, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Sample, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Application, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By End User, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2017–2025 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of APAC
    • Latin America
      • Market Size and Forecast, By Products & Services, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Sample, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Application, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By End User, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2017–2025 (US$ Mn)
        • Brazil
        • Mexico
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Products & Services, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Sample, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Application, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By End User, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2017–2025 (US$ Mn)
        • Central Africa
        • South Africa
        • North Africa
    • Middle East
      • Market Size and Forecast, By Products & Services, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Sample, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Application, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By End User, 2017–2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2017–2025 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
  9. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Roche AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Illumina, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Natera Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Laboratory Corporation of America Holding
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Qiagen N.V.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Thermo Fisher Scientific
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Exact Sciences Corp.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Biocept, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Genomic Health Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Guardant Health
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • CareDx Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Adaptive Biotechnologies Corporatio
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Biocartis SA.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  10.  Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 48 market data tables and 57 figures on "Liquid Biopsy Market - Global forecast to 2025”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.